MEDB-84. The French experience of ELP1-related medulloblastomas. (3rd June 2022)

• Record Type: Journal Article
• Authors: Tauziède-Espariat, Arnault; Guerrini-Rousseau, Léa; Perrier, Alexandre; Torrejon, Jacob; Bernardi, Flavia; Filser, Mathilde; Varlet, Pascale; De Carli, Emilie; Pagnier, Anne; Leblond, Pierre; Faure-Conter, Cécile; Doz, Francois; Bertozzi, Anne-Isabelle; Mansuy, Ludovic; Willems, Marjolaine; Palenzuela, Gilles; Entz-Werle, Natacha; Bourneix, Christine; Hasty, Lauren; Delattre, Olivier; Blauwblomme, Thomas; Beccaria, Kevin; Metais, Alice; Ayrault, Olivier; Chrétien, Fabrice; Bourdeaut, Franck; Dufour, Christelle; Masliah-Planchon, Julien
• Is Part Of: Neuro-oncology. Volume 24(2022)Supplement 1
• Page Start: i126
• Page End: i126
• Publication Date: 2022-06-03
• Subjects: Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noac079.458
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: Medulloblastoma (MB), the most frequent embryonic tumor of the cerebellum is classified into four molecular subgroups (WNT group, SHH group, group 3 and group 4). Although the vast majority of MB are sporadic, predisposing genetic diseases have been described in rare WNT MB and more frequently in the SHH group. In a recent pediatric series of SHH-MB, germline alterations of the ELP1 gene have been described in 14% of cases, making this gene the most frequent genetic predisposition in MB. We have investigated the potential interest of ELP1 immunostaining on a large cohort of 132 MB. A complete loss of ELP1 staining was observed in 12 SHH MB (among 57 total SHH MB: 21%). The loss of ELP1 immunostaining was well correlated with the presence of a bi-allelic alteration of the gene except for one case for which the MB had a loss of ELP1 protein expression demonstrated by immunohistochemistry (IHC) and confirmed by whole proteome analysis, although no obvious genetic alteration in the coding sequence of ELP1 could be found. Molecular analysis of a large "molecular" cohort of 266 MB from French centers for which somatic ELP1 was sequenced allows to identify 12 additional MB with bi-allelic ELP1 genetic alterations. Our results demonstrate the benefit of the ELP1 IHC as an accurate and reliable tool to screen ELP1-deficient MB. This new immunohistochemical tool will now be advantageously used to screen SHH MB upfront for genetic alteration in ELP1, and will subsequently help orientating these patients towards genetic counseling.